Peptides Ranked by Evidence: Which Are Actually Proven?
Share
Not all peptides are backed by the same quality of evidence β and knowing which tier a compound sits in matters more than any hype around it. Some have large, published human trials. Some have only animal data. Some are almost entirely anecdote. This is a plain-English reference ranking the most-discussed peptides by how much human evidence actually backs them, so you can calibrate your expectations before you read another bold claim.
Tier 1 β Strong human evidence
Semaglutide
The most thoroughly studied peptide on this list. The STEP program showed ~15% mean body-weight reduction in people, and the SELECT trial (NEJM, 2023) showed cardiovascular benefit. Multiple large RCTs. This is the benchmark everything else is measured against.
Tirzepatide
Dual GLP-1 + GIP agonist. SURMOUNT-1 (NEJM, 2022) showed ~20β22% mean weight reduction, and a head-to-head trial showed it outperforming semaglutide. Deep human trial base across weight and diabetes.
Tesamorelin
A GHRH analogue with genuine human trial data β notably FDA-approved for a specific indication (reducing visceral fat in a clinical population). Often overlooked in gym conversations, but evidence-wise it belongs in the top tier.
Tier 2 β Promising, thinner data
Retatrutide
Triple agonist with standout Phase 2 results (~24% weight reduction at 48 weeks, NEJM 2023) β but still investigational, with Phase 3 the confirmation step and no approval yet. Class-leading numbers, earlier-stage evidence.
CJC-1295 & Ipamorelin
GH-secretagogue peptides with solid short-term human pharmacology (they reliably raise GH/IGF-1) but limited long-term human outcome data. The mechanism is well characterised; the real-world payoff is not.
BPC-157
An unusually broad and consistent preclinical record for tissue and gut repair β but no completed large human efficacy trials. Sits at the top of Tier 3 / bottom of Tier 2 depending on how generously you weight animal data. Genuinely interesting, genuinely unproven in people.
Tier 3 β Mostly preclinical / anecdotal
TB-500 (Thymosin Ξ²4 fragment)
Repair-focused, supported mainly by preclinical work; its parent protein has reached some early human studies, but TB-500 itself is largely animal data plus user reports.
GHK-Cu
A copper peptide with interesting in-vitro and topical/skin research, but human evidence for the broader systemic claims people make about it is thin.
MOTS-c, Epitalon, and the βlongevityβ peptides
Mechanistically fascinating, heavily marketed, and almost entirely preclinical or theoretical in humans. The excitement runs far ahead of the controlled human data.
How to use this ranking
The tier doesn't tell you a compound is βgoodβ or βbadβ β it tells you how confident you're entitled to be. A Tier 1 result is something thousands of people demonstrated in controlled trials. A Tier 3 result is a hypothesis with promising animal data. Both can be worth researching; they are not the same level of certainty, and anyone blurring that line is selling you something. When you see the next viral claim, the first question is always: which tier is this actually based on?
Read the full cited breakdown of each compound βThis article is educational and not medical advice. Evidence tiers summarise the current state of published research and can change as new trials are published. Tier 3 compounds in particular are not established as safe or effective in humans. Products sold by ThePeptide are intended strictly for in-vitro laboratory research and are not for human consumption. Verify citations on PubMed and consult qualified professionals before drawing conclusions.